Form 4: Pyxis Oncology Officer Granted Significant Equity Awards

Pyxis Oncology's Principal Financial & Accounting Officer, Jitendra Wadhane, received grants of 109,461 restricted stock units and 262,635 stock options.

Summary

• Jitendra Wadhane, Principal Financial & Accounting Officer of Pyxis Oncology, Inc. (PYXS), was granted 109,461 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted on March 24, 2026, at a price of $0, and will vest 25% on March 31, 2026, with the remainder vesting in 36 substantially-equal monthly installments thereafter, contingent on continued employment.
• Following this transaction, Wadhane beneficially owns 512,882 shares of common stock.
• Wadhane also received a grant of 262,635 stock options on March 24, 2026, with an exercise price of $1.36 per share.
• These stock options will vest 25% on March 24, 2027 (the first anniversary of the grant date), and the remainder will vest in 36 equal monthly installments thereafter, subject to continued employment.
• The stock options have an expiration date of March 24, 2036.
• Following this transaction, Wadhane beneficially owns 262,635 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and management retention, as significant equity awards align the Principal Financial & Accounting Officer's interests with long-term shareholder value.

Positives

• The grant of restricted stock units and stock options aligns the Principal Financial & Accounting Officer's interests with long-term shareholder value.
• Equity awards serve as a strong incentive for executive retention and performance.

Risks

• The vesting of both restricted stock units and stock options is contingent upon the reporting person's continued employment through the applicable vesting dates, meaning unvested awards could be forfeited upon departure.

Future Outlook

The equity grants include multi-year vesting schedules, indicating a long-term commitment from the Principal Financial & Accounting Officer to the company's future performance and strategic objectives.

Industry Context

StockSavvy.ai notes that granting equity awards such as restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is widely used to attract, retain, and motivate key personnel by aligning their financial interests with the long-term success and share price performance of the company.

Comparison to Industry Standards

• The structure of these equity grants, with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotech sector, aiming to foster long-term commitment.
• The grant of both RSUs (which provide value regardless of stock price appreciation) and stock options (which incentivize stock price growth) is a common dual-pronged approach to executive incentives in publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grants align management's incentives with shareholder interests, potentially leading to better long-term performance and value creation.
• Employees: This compensation structure for a key executive may signal a commitment to competitive compensation practices within the company.

Next Steps

• The restricted stock units will begin vesting on March 31, 2026, and continue monthly thereafter.
• The stock options will begin vesting on March 24, 2027, and continue monthly thereafter.
• The reporting person's continued employment is required for the vesting of these awards.

Key Dates

Keywords

Pyxis Oncology, PYXS, Jitendra Wadhane, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Executive Compensation, Form 4